Steve Pearson, ICER president (Jeff Rumans)
February 3, 2022 08:00 AM ESTUpdated 09:07 AM
Pharma
Coronavirus

A rar­i­ty for ICER: Cost watch­dog says Covid-19 ther­a­peu­tics ap­pro­pri­ate­ly priced in the US

Zachary Brennan

Senior Editor

Known as a fer­vent watch­dog over the prices and cost-ef­fec­tive­ness of new phar­ma­ceu­ti­cals, the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) said in a re­port …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times